These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 2576057)
1. The systemic availability of buprenorphine administered by nasal spray. Eriksen J; Jensen NH; Kamp-Jensen M; Bjarnø H; Friis P; Brewster D J Pharm Pharmacol; 1989 Nov; 41(11):803-5. PubMed ID: 2576057 [TBL] [Abstract][Full Text] [Related]
2. Intranasal bioavailability of buprenorphine in rabbit correlated to sheep and man. Lindhardt K; Bagger M; Andreasen KH; Bechgaard E Int J Pharm; 2001 Apr; 217(1-2):121-6. PubMed ID: 11292548 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Knoester PD; Jonker DM; Van Der Hoeven RT; Vermeij TA; Edelbroek PM; Brekelmans GJ; de Haan GJ Br J Clin Pharmacol; 2002 May; 53(5):501-7. PubMed ID: 11994056 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers. Bai SA; Xiang Q; Finn A Clin Ther; 2016 Feb; 38(2):358-69. PubMed ID: 26804639 [TBL] [Abstract][Full Text] [Related]
5. Intranasal absorption of buprenorphine--in vivo bioavailability study in sheep. Lindhardt K; Ravn C; Gizurarson S; Bechgaard E Int J Pharm; 2000 Sep; 205(1-2):159-63. PubMed ID: 11000552 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of intravenous, oral transmucosal, and intranasal buprenorphine in healthy male dogs. Enomoto H; Love L; Madsen M; Wallace A; Messenger KM J Vet Pharmacol Ther; 2022 Jul; 45(4):358-365. PubMed ID: 35445748 [TBL] [Abstract][Full Text] [Related]
14. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of ciclesonide and desisobutyryl ciclesonide after administration via aqueous nasal spray or hydrofluoroalkane nasal aerosol compared with orally inhaled ciclesonide: an open-label, single-dose, three-period crossover study in healthy volunteers. Nave R; Herzog R; Laurent A; Wingertzahn MA Clin Ther; 2009 Dec; 31(12):2988-99. PubMed ID: 20110036 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and bioavailability of metoclopramide nasal spray versus metoclopramide intravenous in healthy volunteers and cancer patients. Scaglione F; Scanni A; Tomirotti M; Dimaiuta M; Ferrari P; Fraschini F Arzneimittelforschung; 1993 Sep; 43(9):986-8. PubMed ID: 8240464 [TBL] [Abstract][Full Text] [Related]
17. Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder. Thorsson L; Borgâ O; Edsbäcker S Br J Clin Pharmacol; 1999 Jun; 47(6):619-24. PubMed ID: 10383539 [TBL] [Abstract][Full Text] [Related]
18. Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Adjei A; Sundberg D; Miller J; Chun A Pharm Res; 1992 Feb; 9(2):244-9. PubMed ID: 1553349 [TBL] [Abstract][Full Text] [Related]
19. Comparative study of progesterone plasma levels after nasal spray and intramuscular administration of natural progesterone in menopausal women. Cicinelli E; Savino F; Cagnazzo I; Scorcia P Gynecol Obstet Invest; 1993; 35(3):172-4. PubMed ID: 8505011 [TBL] [Abstract][Full Text] [Related]